Authors
Tyler B Johnson, Katherine A White, Jon J Brudvig, Jacob T Cain, Logan Langin, Melissa A Pratt, Clarissa D Booth, Derek J Timm, Samantha S Davis, Brandon Meyerink, Shibi Likhite, Kathrin Meyer, Jill M Weimer
Publication date
2021/1/6
Journal
Molecular Therapy
Volume
29
Issue
1
Pages
162-175
Publisher
Elsevier
Description
CLN8 disease is a rare form of neuronal ceroid lipofuscinosis caused by biallelic mutations in the CLN8 gene, which encodes a transmembrane endoplasmic reticulum protein involved in trafficking of lysosomal enzymes. CLN8 disease patients present with myoclonus, tonic-clonic seizures, and progressive declines in cognitive and motor function, with many cases resulting in premature death early in life. There are currently no treatments that can cure the disease or substantially slow disease progression. Using a mouse model of CLN8 disease, we tested the safety and efficacy of an intracerebroventricularly (i.c.v.) delivered self-complementary adeno-associated virus serotype 9 (scAAV9) gene therapy vector driving expression of human CLN8. A single neonatal injection was safe and well tolerated, resulting in robust transgene expression throughout the CNS from 4 to 24 months, reducing histopathological and …
Total citations
20212022202320249982